Form 4: Aptevo Director Granted 7,200 Restricted Stock Units

Aptevo Therapeutics Inc. Director Daniel Abdun-Nabi was granted 7,200 Restricted Stock Units, vesting fully on the first anniversary of the grant date.

Summary

• Daniel Abdun-Nabi, a Director of Aptevo Therapeutics Inc. (APVO), was granted 7,200 Restricted Stock Units (RSUs).
• The grant date for these RSUs is August 6, 2025.
• Each RSU converts into one share of Aptevo Therapeutics Inc. common stock.
• The RSUs will vest in full on the first anniversary of the grant date.
• Following this transaction, Daniel Abdun-Nabi beneficially owns 7,200 RSUs directly.

Sentiment

Score: 6

Explanation: The grant of Restricted Stock Units to a director is a positive sign of alignment between management and shareholder interests, as the director's compensation is tied to the company's stock performance. However, it is a routine compensation event and does not indicate significant new developments.

Positives

• Grant of RSUs to a director aligns their interests with shareholders, as the value of the RSUs is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment from the director.

Negatives

• No immediate cash inflow for the director from this grant, as it is equity-based compensation.
• Potential minor dilution for existing shareholders upon vesting and conversion of RSUs into common stock.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This is a routine insider transaction, common for directors to receive equity compensation in publicly traded companies, particularly in the biotech and pharmaceutical sectors.

Comparison to Industry Standards

• Restricted Stock Unit (RSU) grants are a standard form of equity compensation for directors in publicly traded companies.
• The mechanism of granting RSUs that vest over time is consistent with common corporate governance practices aimed at aligning director incentives with long-term shareholder value.

Related Party Transactions

• Grant of 7,200 Restricted Stock Units to Daniel Abdun-Nabi, a Director of Aptevo Therapeutics Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential minor dilution upon RSU vesting; improved alignment of director's interests with shareholder value.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• The 7,200 Restricted Stock Units are expected to vest in full on August 6, 2026, which is the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice. It does not provide new information that would significantly alter the investment thesis for Aptevo Therapeutics Inc. Therefore, a 'hold' recommendation is appropriate, as this event alone does not warrant a change in investment stance.

Keywords

Aptevo Therapeutics, APVO, Restricted Stock Units, RSU, Insider Trading, Director Compensation, Equity Grant, Form 4, Daniel Abdun-Nabi